Byoung Ryu

Title: Byoung RYU: Innovator in Chimeric Antigen Receptor Technology

Introduction

Byoung RYU is a prominent inventor based in South San Francisco, CA, USA. He is recognized for his contributions to the field of immunotherapy, particularly through his work on chimeric antigen receptors (CARs). With a focus on enhancing T cell therapy, RYU has developed innovative solutions that hold the potential to significantly improve cancer treatment outcomes.

Latest Patents

Byoung RYU holds one patent titled "ROR1 targeting chimeric antigen receptor". This patent encompasses polynucleotides encoding a chimeric polypeptide that includes a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. It also describes T cells expressing CARs that comprise a ROR1-binding protein while overexpressing a c-Jun polypeptide. The overexpression of c-Jun in CAR T cells is reported to confer improved characteristics, such as reducing or preventing exhaustion in these therapeutic cells.

Career Highlights

Byoung RYU is currently employed at Lyell Immunopharma, Inc., where he leverages his expertise to advance CAR T cell technologies. His research focuses on developing innovative therapies that aim to elevate the efficacy of immune responses against cancer.

Collaborations

Throughout his professional journey, RYU has collaborated with talented individuals in the field, including Spencer PARK and Queenie VONG. These partnerships enhance the progress of their collective research endeavors, pushing the boundaries of what is achievable in immunotherapy.

Conclusion

In conclusion, Byoung RYU is a visionary inventor whose work on ROR1 targeting chimeric antigen receptors represents a significant advancement in cancer therapy. His dedication to improving T cell functionality through innovative approaches is helping pave the way for future breakthroughs in the treatment of cancer.